Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr-Jun;108(2):368504251336066.
doi: 10.1177/00368504251336066. Epub 2025 Apr 15.

Survival rates at one and five years for patients with group 1 pulmonary arterial hypertension at high altitude: A retrospective cohort study

Rafael Conde-Camacho  1   2 , Eduardo Tuta-Quintero  3 , Alirio Bastidas-Goyes  2 , Luis F Giraldo-Cadavid  3   4 , Oscar Barón  1   3 , Angelica Mora  3
Affiliations

Survival rates at one and five years for patients with group 1 pulmonary arterial hypertension at high altitude: A retrospective cohort study

Rafael Conde-Camacho et al. Sci Prog. 2025 Apr-Jun.

Abstract

ObjectivesGroup 1 pulmonary arterial hypertension (PAH) causes increased vascular resistance, right heart failure, and reduced survival. High-altitude PAH survival data are limited despite chronic hypoxia's potential impact on disease progression and risk stratification. The objective was to evaluate survival stratified by the European Society of Cardiology/European Respiratory Society (ESC/ERS) baseline risk score, REVEAL risk score 2.0, and etiologies in patients with PAH at high altitudes.MethodsA retrospective cohort study was conducted to evaluate functional and hemodynamic variables and risk stratification using the ESC/ERS baseline risk score and REVEAL risk score 2.0. One-year and five-year survival rates were determined from admission to the pulmonary hypertension program until death or the end of follow-up.ResultsA total of 188 patients were included. The overall survival rate at one year was 95.8%, and at five years it was 86.8%. Precisely, 50% (95 out of 188) had congenital heart disease, 34% (63 out of 188) had idiopathic, and 13% (24 out of 188) had connective tissue disease. Risk stratification using REVEAL risk score 2.0 classified 58% (109 out of 188) of patients as low risk, 26% as intermediate risk, and 16% (30 out of 188) as high risk. Using the ESC/ERS baseline risk score, Stratification indicated 78% (146 out of 188) low risk, 21% (40 out of 188) intermediate risk, and 1% (2 out of 188) high risk. High risk according to ESC/ERS baseline risk score (p < 0.001) and REVEAL risk score 2.0 (p < 0.001) was associated with lower survival. Idiopathic etiology was associated with a lower survival rate (p = 0.011).ConclusionThe survival of patients with PAH at a high-altitude expert center was 95.8% at one year and 86.8% at five years. Risk stratification using the REVEAL risk score 2.0 and the ESC/ERS baseline risk score was associated with higher mortality in patients classified as high risk.

Keywords: Pulmonary hypertension; altitude; observational study; survival; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Study flowchart.
Figure 2.
Figure 2.
One-year and five-year survival.
Figure 3.
Figure 3.
Survival analysis by European Society of Cardiology/European Respiratory Society (ESC/ERS) baseline risk score.
Figure 4.
Figure 4.
Survival analysis by REVEAL risk score 2.0.
Figure 5.
Figure 5.
Survival analysis by etiology of pulmonary arterial hypertension group I.
See this image and copyright information in PMC

References

    1. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012; 142: 448–456. - PubMed
    1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–223. - PubMed
    1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618–3731. - PubMed
    1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European Paediatric and Congenital Cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J 2016; 37: 67–119. - PubMed
    1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. - PMC - PubMed

LinkOut - more resources